Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zhaoke Ophthalmology's Enterprise Value is HK$-532.93 Mil.
Zhaoke Ophthalmology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-411.88 Mil. Therefore, Zhaoke Ophthalmology's EV-to-EBIT ratio for today is 1.29.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Zhaoke Ophthalmology's Enterprise Value is HK$-532.93 Mil.
Zhaoke Ophthalmology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-411.88 Mil. Therefore, Zhaoke Ophthalmology's EV-to-EBITDA ratio for today is 1.29.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Zhaoke Ophthalmology's Enterprise Value is HK$-532.93 Mil.
Zhaoke Ophthalmology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$20.51 Mil. Therefore, Zhaoke Ophthalmology's EV-to-Revenue ratio for today is -25.99.
Zhaoke Ophthalmology Enterprise Value Historical Data
The historical data trend for Zhaoke Ophthalmology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zhaoke Ophthalmology's Enterprise Value
For the Biotechnology subindustry, Zhaoke Ophthalmology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Enterprise Value falls into.
Zhaoke Ophthalmology Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Zhaoke Ophthalmology's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (HKSE:06622) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Zhaoke Ophthalmology's current Enterprise Value is HK$-532.93 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-411.88 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Zhaoke Ophthalmology's current Enterprise Value is HK$-532.93 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-411.88 Mil.
Zhaoke Ophthalmology's current Enterprise Value is HK$-532.93 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$20.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology Enterprise Value Related Terms
Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhaoke Ophthalmology (HKSE:06622) Business Description
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06622 has been successfully added to your 